A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies-Reference-Cited by-同舟云学术

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

Published:2019-04-30 Issue:2 Volume:38 Page:445-456
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Yamamoto Noboru,Ryoo Baek-Yeol,Keam Bhumsuk,Kudo Masatoshi,Lin Chia-Chi,Kunieda Futoshi,Ball Howard A.,Moran Diarmuid,Komatsu Kanji,Takeda Kentaro,Fukuda Musashi,Furuse Junji,Morita Satoshi,Doi Toshihiko

Funder

Astellas Pharma Inc

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-019-00780-w.pdf

Reference13 articles.

1. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2017) Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget 8(9):16052–16074. https://doi.org/10.18632/oncotarget.14109

2. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3):235–253. https://doi.org/10.1038/nrd2792

3. Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC (2015) Targeting FGFR signaling in cancer. Clin Cancer Res 21(12):2684–2694. https://doi.org/10.1158/1078-0432.ccr-14-2329